Biotech Essentials

Companies & Industries

Biotech Companies & Industries Essentials publishes only the best Biotech news and links, carefully hand-picked and curated by top biotech experts.

Top news of the week: 06.05.2021.

#biotechnology
#BIODigital
#pharmaceuticals
#dermatology
#atopiceczema
#NBTintheNews
#moversandshakers
#fda
#lifesciences
#COVID19

Companies And Industries

@kiranshaw shared
On May 4, 2021
RT @FiercePharma: BioNTech, with partner Pfizer, on track to make 3B COVID vaccine doses in 2021, CEO says https://t.co/nL8jcUFKGd
Open
BioNTech, with partner Pfizer, on track to make 3B COVID vaccine doses in 2021, CEO says

BioNTech, with partner Pfizer, on track to make 3B COVID vaccine doses in 2021, CEO says

BioNTech and U.S. partner Pfizer will be able to produce nearly 3 billion doses in 2021, higher than a previously estimated 2.5 billion doses, BioNTech CEO Ugur Sahin told the Financial ...

@NatureBiotech shared
On May 4, 2021
Researchers wirelessly record human brain activity during normal life activities #NBTintheNews https://t.co/63rl8pnapA
Open
Researchers wirelessly record human brain activity during normal life activities

Researchers wirelessly record human brain activity during normal life activities

NIH BRAIN Initiative-funded study opens the door to correlating deep brain activity and behavior.

@IAmBiotech shared
On May 3, 2021
RT @BIOConvention: Join us for the #BIODigital keynote, "Breaking Barriers in Vaccine Development" featuring @AlbertBourla, Chairman and CEO of @Pfizer, to learn about vaccine development, the future of biotech, and more. (Brought to you by @Avantor_News). See session here: https://t.co/ufkFLDTIE3 https://t.co/fv5rWpbz02
Open
Breaking Barriers in Vaccine Development: A Conversation with Dr. Albert Bourla, Chairman and Chief Executive Officer of Pfizer

Breaking Barriers in Vaccine Development: A Conversation with Dr. Albert Bourla, Chairman and Chief Executive Officer of Pfizer

The Biotechnology Innovation Organization is the world's largest biotech trade association. Learn about BIO, register for events and explore member services.

@Biotechnology shared
On May 1, 2021
FDA CRL Hurdle for LEO Pharma on Tralokinumab https://t.co/qpQeT5k3js https://t.co/LXSGtjPnOX
Open
FDA CRL Hurdle for LEO Pharma on Tralokinumab

FDA CRL Hurdle for LEO Pharma on Tralokinumab

The U.S. FDA has released a Complete Response Letter (CRL) following its review of LEO Pharma’s tralokinumab. Further data on a device component is the issue brought to light by the ...

@Biotechnology shared
On May 5, 2021
Money on the Move: April 29 – May 4 https://t.co/YS33dPOXlt https://t.co/YMM9T7BvHu
Open
Money on the Move: April 29 – May 4

Money on the Move: April 29 – May 4

April showers bring May dollars. Here's whose cash gardens are really blooming this week in the life sciences world.

@Biotechnology shared
On May 5, 2021
Four New Biotechs to Watch: Esker, Mogrify, Isolere and BridGene https://t.co/QQBqZIZtDK https://t.co/g8O4REIyH5
Open
Four New Biotechs to Watch: Esker, Mogrify, Isolere and BridGene

Four New Biotechs to Watch: Esker, Mogrify, Isolere and BridGene

There’s money on the move and venture capital firms launch several biotech companies with hefty Series A financing rounds. Here’s a look.

@pharmaphorum shared
On May 6, 2021
New UK #biotech @Inspira_pharma partners with @VecturaGroup on an inhaled therapy for #COVID19 based on plant extracts that CEO says could be in human trials within 12 months https://t.co/FgNP5xQ5b7
Open
New UK biotech Inspira uncloaks with deal to develop inhaled COVID therapy

New UK biotech Inspira uncloaks with deal to develop inhaled COVID therapy

UK biotech Inspira Pharmaceuticals has emerged from stealth mode with a deal with Vectura to develop an inhaled

@FierceBiotech shared
On Apr 30, 2021
Failure against the primary and secondary endpoints torpedoed Cara’s stock price but didn’t stop the biotech from plotting out a path forward for oral Korsuva in atopic dermatitis https://t.co/x0tt5XRPha
Open
Cara's stock tanks as atopic dermatitis phase 2 misses endpoint

Cara's stock tanks as atopic dermatitis phase 2 misses endpoint

A phase 2 trial of Cara Therapeutics’ anti-itch treatment has missed its primary endpoint, sending the biotech’s stock price down 45%. Yet, Cara is forging ahead in atopic dermatitis on the ...